CRIS Current Research Information System

ZINZANI, PIER LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 34.242
NA - Nord America 32.095
EU - Europa 22.686
SA - Sud America 2.437
AF - Africa 1.409
OC - Oceania 75
Continente sconosciuto - Info sul continente non disponibili 24
Totale 92.968
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.541
SG - Singapore 9.132
CN - Cina 9.002
VN - Vietnam 8.095
GB - Regno Unito 4.522
IT - Italia 4.011
DE - Germania 2.975
NL - Olanda 2.592
HK - Hong Kong 2.274
SE - Svezia 2.254
BR - Brasile 1.780
FR - Francia 1.508
IN - India 1.450
KR - Corea 1.196
RU - Federazione Russa 1.181
BD - Bangladesh 943
UA - Ucraina 811
IE - Irlanda 692
JP - Giappone 639
FI - Finlandia 608
ZA - Sudafrica 468
CI - Costa d'Avorio 316
EE - Estonia 309
AR - Argentina 278
CA - Canada 274
ID - Indonesia 216
TG - Togo 203
CH - Svizzera 197
PH - Filippine 172
AT - Austria 164
MX - Messico 160
PL - Polonia 150
JO - Giordania 147
TH - Thailandia 138
HR - Croazia 133
SC - Seychelles 120
IQ - Iraq 114
ES - Italia 104
TR - Turchia 104
EC - Ecuador 98
BG - Bulgaria 93
TW - Taiwan 90
BE - Belgio 89
NG - Nigeria 83
PK - Pakistan 76
SA - Arabia Saudita 73
CL - Cile 64
AU - Australia 60
CO - Colombia 59
IR - Iran 58
GR - Grecia 55
UZ - Uzbekistan 47
VE - Venezuela 47
EG - Egitto 45
PY - Paraguay 44
MY - Malesia 38
LB - Libano 36
MA - Marocco 32
LT - Lituania 31
PE - Perù 31
RO - Romania 30
IL - Israele 27
DZ - Algeria 25
CZ - Repubblica Ceca 24
AE - Emirati Arabi Uniti 23
TN - Tunisia 23
AL - Albania 22
KE - Kenya 22
LU - Lussemburgo 21
AZ - Azerbaigian 19
KZ - Kazakistan 19
DO - Repubblica Dominicana 18
EU - Europa 18
BO - Bolivia 17
JM - Giamaica 17
OM - Oman 16
PT - Portogallo 16
RS - Serbia 16
UY - Uruguay 16
ET - Etiopia 15
NP - Nepal 15
CR - Costa Rica 14
DK - Danimarca 13
HU - Ungheria 12
NZ - Nuova Zelanda 11
GT - Guatemala 10
PA - Panama 10
PR - Porto Rico 10
TT - Trinidad e Tobago 9
BY - Bielorussia 8
GH - Ghana 8
GE - Georgia 7
HN - Honduras 7
KG - Kirghizistan 7
LY - Libia 7
MD - Moldavia 7
SK - Slovacchia (Repubblica Slovacca) 7
SN - Senegal 7
AM - Armenia 6
AO - Angola 6
Totale 92.807
Salva come PNG Salva come JPEG
Città #
Singapore 6.305
Southend 3.817
Ashburn 3.155
Fairfield 3.121
Hefei 2.545
Hong Kong 2.150
San Jose 2.122
Ho Chi Minh City 1.885
Chandler 1.649
Hanoi 1.532
Woodbridge 1.505
Houston 1.491
Seattle 1.394
Wilmington 1.370
Eygelshoven 1.296
Santa Clara 1.118
Cambridge 1.110
Princeton 1.090
Seoul 1.086
Ann Arbor 1.038
Beijing 842
Boardman 834
Dong Ket 762
Lauterbourg 728
Dublin 692
Kerkrade 666
Bologna 649
Los Angeles 583
New York 555
Tokyo 544
Frankfurt am Main 543
Helsinki 465
Nanjing 422
Jacksonville 419
Council Bluffs 416
Milan 412
Westminster 412
Buffalo 348
Dallas 348
Berlin 342
Padova 337
Abidjan 316
Da Nang 269
Haiphong 247
Jinan 236
Bengaluru 234
São Paulo 223
Redondo Beach 211
Lomé 202
San Diego 197
Shenyang 195
Saint Petersburg 192
Rome 186
Changsha 174
Chicago 164
Guangzhou 162
Turin 157
Nuremberg 148
Amman 145
Shanghai 142
Hebei 134
Nanchang 131
Tianjin 131
London 129
Bern 127
Jakarta 124
Zhengzhou 120
Bremen 119
Munich 119
Lappeenranta 111
Hangzhou 100
Phoenix 98
Warsaw 98
Mülheim 94
Redmond 93
Redwood City 93
Des Moines 92
Florence 92
Jiaxing 90
Biên Hòa 89
The Dalles 89
Toronto 88
Johannesburg 85
Sofia 84
Amsterdam 83
Hyderabad 82
Hải Dương 82
Falls Church 80
Olalla 78
Dearborn 76
Vienna 75
Yubileyny 75
Falkenstein 72
Brussels 71
Norwalk 69
Can Tho 68
Rio de Janeiro 68
Taizhou 68
Thái Nguyên 67
Orem 66
Totale 59.608
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.851
Consensus conference on the management of tumor lysis syndrome. 471
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 446
Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. 364
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 330
18F-FDG PET early after radiotherapy in lymphoma patients. 319
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 317
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 290
Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets 289
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 285
Biology and treatment of follicular lymphoma. 282
Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review 277
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium 271
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 269
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 265
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 258
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 256
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 256
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 252
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 252
A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine 251
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 250
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 246
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 245
18 F-FDG PET in malignant lymphoma: significance of positive findings 244
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 243
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome 243
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 240
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 239
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity 236
Detection of Brain-Derived Cell-Free DNA in Plasma 233
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 231
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 231
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. 227
T-Cell Lymphomas in South America and Europe 227
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 226
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 226
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 223
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 222
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. 222
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 222
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 222
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 222
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 222
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma 221
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy 221
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 221
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 220
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 218
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 217
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 217
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program 217
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 212
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 210
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 210
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 209
RALE051: a novel established cell line of sporadic Burkitt lymphoma 209
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 208
Expression of CD52 in peripheral T-cell lymphoma. 208
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 208
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 208
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 206
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 205
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients 205
Lymphoma: diagnosis, staging, natural history, and treatment strategies. 203
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 203
Primary non-hodgkin’s lymphoma of bone: treatment and analysis of prognostic factors for stage I and stage II 201
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study 200
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 200
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 200
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 200
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 200
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 199
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 197
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 195
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 195
CD30 expression in peripheral T-cell lymphomas 195
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 195
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 194
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 194
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 192
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 191
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 191
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 191
Histopathology of B-cell chronic lymphocytic leukemia. 190
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. 190
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial 190
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma 190
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. 190
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial 190
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 190
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 188
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 186
The role of mitoxantrone in the treatment of indolent lymphomas. 186
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. 186
Autologous hematopoietic stem cell transplantation in Non-Hodgkin's lymphomas. 185
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 185
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 184
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 184
Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials 183
Totale 25.376
Salva come PNG Salva come JPEG
Categoria #
all - tutte 259.539
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 259.539
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.948 0 0 0 0 0 0 0 0 0 0 0 1.948
2021/20228.269 901 251 567 737 812 444 178 671 307 477 1.593 1.331
2022/20238.447 973 1.102 503 1.028 698 601 280 540 1.390 301 606 425
2023/20242.799 180 449 201 270 223 374 177 180 98 278 218 151
2024/202514.004 430 2.120 1.121 963 1.794 681 1.165 392 347 1.025 1.003 2.963
2025/202639.343 3.055 4.480 3.615 2.872 3.298 3.296 4.539 1.990 5.850 2.616 2.049 1.683
Totale 94.824